<DOC>
	<DOCNO>NCT00411736</DOCNO>
	<brief_summary>In patient Cystic Fibrosis , recurrent airway infection cause Pseudomonas aeruginosa ultimately lead chronic airway infection . The purpose study determine whether supplementary low-dose azithromycin standard inhale colistin oral ciprofloxacin treatment intermittent pseudomonas airway-infection postpone next episode intermittent pseudomonas airway-infection prevent development chronic airway-infection .</brief_summary>
	<brief_title>Scandinavian Cystic Fibrosis Azithromycin Study</brief_title>
	<detailed_description>Cystic Fibrosis common genetic , inherit , deadly disease caucasian . The disease characterize recurrent airway-infections cause Pseudomonas aeruginosa , ultimately lead chronic airway-infection , main cause increase morbidity mortality see disease . P. aeruginosa ability change mucoid phenotype - produce alginate grow biofilm , protect microorganisms antibiotic leukocyte . The change phenotype see chronic infection establish eradication become impossible . Treatment long-term , low-dose azithromycin chronically infect CF-patients improve clinical condition patient . The exact mechanism know , possibly combination anti-inflammatory effect ability azithromycin inhibit alginate-production . Inhibition biofilm-formation leave bacteria susceptible action antibiotic leukocyte . Prior establishment chronic infection , recurrent , intermittent colonization airways non-mucoid P. aeruginosa see . Intermittent infection treat use combination antibiotic , thereby postpone next episode airway-infection P. aeruginosa . The purpose study clarify wether supplementary azithromycin treatment intermittent pseudomonas-infection CF-patients lead postponement next pseudomonas-colonization maybe prevent development chronic infection . This do randomise , double-blinded , placebo-controlled multicentre study . 2 treatment compare : 1 . Inhaled colistin oral ciprofloxacin combination oral azithromycin 2 . Inhaled colistin oral ciprofloxacin combination oral placebo . The treatment give 3 week , primary end-point time next colonization P. aeruginosa airways patient , compare 2 treatment-groups .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Diagnosis Cystic Fibrosis base genotype and/or positive sweattest Written inform consent base write spoken information No chronic airwayinfections Gramnegative bacteria Fertile , sexually active woman must use contraception ( ppills , IUD method similar Pearlindex ) participate study P. aeruginosa airway secretion obtain less 3 month prior inclusion Chronic infection airway cause Gramnegative bacteria ( Burkholderia specie , Achromobacter xylosoxidans , Pandorea apista Stenotrophomonas maltophilia ) Chronic infection airway cause P. aeruginosa ( chronic infection define continue growth microorganism 6 month and/or increase specific , precipitate antibody level least 2 ) Previous infection strain P. aeruginosa resistant ciprofloxacin colistin Previous participation pseudomonasvaccinationstudy Patients young 1 year Pregnant lactating woman , sexually active woman unwilling use safe contraception ( ppills , IUD method similar Pearlindex ) participate study Severe insufficiency liver kidney judge local investigator</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Intermittent pulmonary infection</keyword>
</DOC>